Brief: Pharnext Announces First Patient Enrolled In Open Label Extension Of Phase III Study Of PXT3003
12/09/2022 07:34
Sept 12 (Reuters) - Pharnext SA PHARN.PA :
* PHARNEXT ANNOUNCES FIRST PATIENT ENROLLED IN OPEN LABEL
EXTENSION OF PIVOTAL PHASE III STUDY OF PXT3003 FOR TREATMENT OF
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A, PREMIER TRIAL
Source text for Eikon: ID:nEQc9N1gFa
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development